menu
    • menu
    [{"orgOrder":0,"company":"Cyclotek","sponsor":"Radiopharm Theranostics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2025","type":"Agreement","leadProduct":"161-Tb RAD 402","moa":"KLK3","graph1":"Oncology","graph2":"Preclinical","graph3":"Cyclotek","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cyclotek \/ Cyclotek","highestDevelopmentStatusID":"4","companyTruncated":"Cyclotek \/ Cyclotek"}]

    Find Clinical Drug Pipeline Developments & Deals by Cyclotek

    Menu

    Cyclotek

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cyclotek

                            Australia arrow
                            PREP
                            Not Confirmed

                            Cyclotek

                            Australia arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 161-Tb RAD 402

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Radiopharm Theranostics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Radiopharm and Cyclotek Sign Clinical Supply Agreement for ¹⁶¹Tb-KLK3-mAb

                            Details : The agreement aims to supply radiolabel RAD 402, an anti-KLK3 monoclonal antibody, with Terbium-161 (161Tb) in Australia, which supports the initiation of a Phase 1 clinical trial.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Undisclosed

                            June 24, 2025

                            Lead Product(s) : 161-Tb RAD 402

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Radiopharm Theranostics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth